Park J, Kim S, Oh JK, Kim JY, Yoon SS, Lee D, Kim Y
J Biochem Mol Biol. 2005 Nov 30; 38(6): 725-38

Resistance to imatinib mesylate (also known as Gleevec, Glivec, and STI571) often becomes a barrier to the treatment of chronic myelogenous leukemia (CML). In order to identify markers of the action of imatinib mesylate, we used a mass spectrometry approach to compare protein _expression_ profiles in human leukemia cells (K562) and in imatinib mesylate-resistant human leukemia cells (K562-R) in the presence and absence of imatinib mesylate.

--
Posted by Rob to CML Newswire: Medical And Technical News On Chronic Myelogenous Leukemia at 12/15/2005 01:09:06 AM


New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com

Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com

CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com

Post Message: [email protected]
Subscribe:  [EMAIL PROTECTED]
Unsubscribe:  [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED] 
CML Group Web Site http://groups.yahoo.com/group/CML




SPONSORED LINKS
Chronic myelogenous leukemia Leukemia treatment Cml


YAHOO! GROUPS LINKS




Reply via email to